Unknown

Dataset Information

0

Effect of Jardiance on glucose uptake into astrocytomas.


ABSTRACT:

Purpose

SGLT2, the sodium glucose cotransporter two, is expressed in human pancreatic, prostate and brain tumors, and in a mouse cancer model SGLT2 inhibitors reduce tumor glucose uptake and growth. In this study we have measured the effect of a specific SGLT2 inhibitor, Jardiance® (Empagliflozin), on glucose uptake into astrocytomas in patients.

Methods

We have used a specific SGLT glucose tracer, α-methyl-4-[18F]fluoro-4-deoxy-α-D-glucopyranoside (Me4FDG), and Positron Emission Tomography (PET) to measure glucose uptake. Four of five patients enrolled had WHO grade IV glioblastomas, and one had a low grade WHO Grade II astrocytoma. Two dynamic brain PET scans were conducted on each patient, one before and one after treatment with a single oral dose of Jardiance, a specific SGLT2 inhibitor. As a control, we also determined the effect of oral Jardiance on renal SGLT2 activity.

Results

In all five patients an oral dose (25 or 100 mg) of Jardiance reduced Me4FDG tumor accumulation, highly significant inhibition in four, and inhibited SGLT2 activity in the kidney.

Conclusions

These initial experiments show that SGLT2 is a functional glucose transporter in astocytomas, and Jardiance inhibited glucose uptake, a drug approved by the FDA to treat type 2 diabetes mellitus (T2DM), heart failure, and renal failure. We suggest that clinical trials be initiated to determine whether Jardiance reduces astrocytoma growth in patients.

SUBMITTER: Ghezzi C 

PROVIDER: S-EPMC11341586 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of Jardiance on glucose uptake into astrocytomas.

Ghezzi Chiara C   Ellingson Benjamin M BM   Lai Albert A   Liu Jie J   Barrio Jorge R JR   Wright Ernest M EM  

Journal of neuro-oncology 20240722 2


<h4>Purpose</h4>SGLT2, the sodium glucose cotransporter two, is expressed in human pancreatic, prostate and brain tumors, and in a mouse cancer model SGLT2 inhibitors reduce tumor glucose uptake and growth. In this study we have measured the effect of a specific SGLT2 inhibitor, Jardiance® (Empagliflozin), on glucose uptake into astrocytomas in patients.<h4>Methods</h4>We have used a specific SGLT glucose tracer, α-methyl-4-[<sup>18</sup>F]fluoro-4-deoxy-α-D-glucopyranoside (Me4FDG), and Positro  ...[more]

Similar Datasets

| S-EPMC11485312 | biostudies-literature
| S-EPMC2565063 | biostudies-literature
2006-05-01 | GSE4414 | GEO
2023-07-07 | GSE235398 | GEO
| S-EPMC6700976 | biostudies-literature
2010-03-06 | E-GEOD-20566 | biostudies-arrayexpress
| S-EPMC6629077 | biostudies-literature
2010-03-02 | GSE20566 | GEO
| S-EPMC6780013 | biostudies-literature
| S-EPMC8147615 | biostudies-literature